Oculis Holding AG Ordinary shares (OCS)
Stock · NASDAQ · Health Care
$12.21as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Resistance level
$26.67
Industry
Biotechnology: Pharmaceutical Preparations
About OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 60
- Website
- oculis.com
Fundamentals
- 1-day range
- $12.41$13.28
- Market cap
- $717.85M
- P/E (trailing)
- —
- P/E (forward)
- -6.16
- EPS (trailing)
- $-1.71
- Dividend yield
- —
- Beta
- 0.23
- Avg. volume
- 690.4K
52-week range
$10.52$34.48
Next earnings: November 5, 2026 · EPS estimate $-0.37
Forecasts
10 analyst ratings
Buy 100%
Hold 0%
Sell 0%
1-year price forecast
High
$44.96
+268.2%
Median
$39.07
+220.0%
Low
$22.37
+83.2%
Oculis Holding AG Ordinary shares Competitors
Chosen by industry and closest market cap.
- OCSOculis Holding AG Ordinary shares$12.21▼ 1.77%Market cap $717.85MP/E —$10.52$34.48
- CTMXCytomX Therapeutics Inc. Common Stock$3.22▼ 5.99%Market cap $733.66MP/E —$1.9$8.21
- CYRXCryoPort Inc. Common Stock$16.08▼ 2.96%Market cap $741.42MP/E —$7.61$17.2
- EVOEvotec SE American Depositary Shares$1.91▼ 2.80%Market cap $693.72MP/E —$3.18$7.3
- NGNENeurogene Inc. Common Stock$36.38▼ 3.91%Market cap $680.52MP/E —$15.93$43.66
- PHARPharming Group N.V. ADS each representing 10 ordinary shares$11.7▼ 0.68%Market cap $766.28MP/E 88.15$0.8338$1.82
- DRUGBright Minds Biosciences Inc. Common Stock$72.74▼ 2.41%Market cap $792.81MP/E —$53.99$170
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OCS Oculis Holding AG Ordinary shares | $717.85M | — | $12.21 | ▼ 1.77% | $10.52$34.48 |
| CTMX CytomX Therapeutics Inc. Common Stock | $733.66M | — | $3.22 | ▼ 5.99% | $1.9$8.21 |
| CYRX CryoPort Inc. Common Stock | $741.42M | — | $16.08 | ▼ 2.96% | $7.61$17.2 |
| EVO Evotec SE American Depositary Shares | $693.72M | — | $1.91 | ▼ 2.80% | $3.18$7.3 |
| NGNE Neurogene Inc. Common Stock | $680.52M | — | $36.38 | ▼ 3.91% | $15.93$43.66 |
| PHAR Pharming Group N.V. ADS each representing 10 ordinary shares | $766.28M | 88.15 | $11.7 | ▼ 0.68% | $0.8338$1.82 |
| DRUG Bright Minds Biosciences Inc. Common Stock | $792.81M | — | $72.74 | ▼ 2.41% | $53.99$170 |
P/E shows — for peers not currently carrying a live signal of their own.
See the full, filterable feed with live charts on the MarketWall dashboard.